Second line treatment of non-small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 385-387, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-467412
ABSTRACT
The cytotoxic agents pemetrexed and docetaxel and the epidermal growth factor receptor (EGFR)tyrosine kinase inhibitors(TKIs)erlotinib and gefitinib are standard second-line therapies for non-small cell lung cancer. For patients without the EGFR mutation,more and more evidence has suggested the superiority of chemotherapy over targeted therapy. Adding targeted agents to standard second-line treatment is an trend of exploration,but without promising results nowadays. Crizotinib,targeting at anaplastic lymphoma kinase,has been shown excellent efficacy for second-line therapy in non-small cell lung cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Oncology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS